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ABSTRACT
One hundred ninety patients underwent 197 HLA-matched related allogeneic stem cell transplantation for a
diagnosis of  thalassemia major at our center. The median age (SD) was 7  4.1 years, and there were 129
(68%) males. Age and liver size as continuous variables were significantly associated with an adverse outcome.
Using a receiver operator characteristics curve plot analysis, cutoff values of 7 years and 5 cm for age and liver
size, respectively, were associated with the highest likelihood ratio of an adverse impact. On a multivariate
analysis age >7 years and liver size >5 cm had a significant impact on event free survival (EFS) (relative risk
2.2 and 2.7, P values .014 and .000, respectively). Using these 2 variables, patients were categorized as high risk
if they were >7 years and had a liver size >5 cm (n  41; all belonged to Class III). The 5-year EFS and overall
survival (OS) in this high-risk group was 23.93  6.88 and 39.01  7.96, whereas in the remaining Class III
patients (n  64) it was 70.3  6.06 and 78.3  5.5, respectively. This risk stratification identifies a significant
subset (39%) of patients among those in Class III who have a poor outcome with a conventional myeloablative
allogeneic stem cell transplantation. Patients in this high-risk group would probably benefit from novel
therapeutic approaches.
© 2007 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Allogeneic stem cell transplantation (SCT) re-
ains the only curative option for patients with 
halassemia major. The correction of this disorder by
n allogeneic stem cell transplant was ﬁrst described
y Thomas et al. [1]. Subsequently, a conditioning
egimen of busulphan and cyclophosphamide was es-
ablished for SCT in this condition [2]. This myeloa-
lative therapy forms the basis for the currently used
onditioning regimens in this condition. The current
isk stratiﬁcation of patients with  thalassemia major
ndergoing a myeloablative allogeneic SCT classiﬁes them into 3 risk groups (Lucarelli Class I, II, and III),
ased on liver size (2 cm), presence of liver ﬁbrosis,
nd inadequate iron chelation [3,4]. Patients with
one of the above risk factors are classiﬁed as Class I,
hose with 1 or 2 of these risk factors as Class II,
hereas those patients who have all 3 adverse risk
actors are classiﬁed as Class III. Patients in Class I
nd II are considered to be low risk and have an
xcellent long-term outcome following an allogeneic
CT [3,4]. Class III patients, on the other hand, are
onsidered high risk and have inferior outcomes fol-
owing an SCT, leading to evaluation of novel condi-
ioning regimens in this group [3-7]. However, in a
889
p
t
n
b
r
w
c
d
q
F
h
s
I
w
w
S
t
a
p
P
i
b
S
P
c
h
v
l
t
t
y
H
C
u
n
o
p
c
t
B
p
a
w
r
p
F
p
g
s
G
G
a
d
i
r
d
n
m
1
h
b
c
t
v
m
G
i
S
H
r
d
t
d
t
t
a
t
d
d
n
D
p
e
c
f
p
f
t
f
t
S
b
f
V. Mathews et al.890opulation with poor medical treatment prior to SCT,
he above risk stratiﬁcation is limited by the small
umber of patients who belong to Class I, the majority
eing in Class III. In such a population, the current
isk stratiﬁcation strategy is also insensitive to the
ide heterogeneity among patients in Class III. In-
reasingly, allogeneic SCT is being offered in many
eveloping countries where this scenario of inade-
uate medical treatment prior to SCT is common.
inally, the above risk factors and risk stratiﬁcation
as not been validated in different populations, more
o in developing countries where the proﬁle of Class
II patients are likely to be very variable.
Our clinical observation suggested that patients
ho belong to Class III were a heterogenous group
ith varying clinical outcomes following an allogeneic
CT. We undertook a retrospective analysis of pa-
ients with  thalassemia major who underwent an
llogeneic stem cell transplant at our center to study
arameters that had an impact on clinical outcome.
ATIENTS AND METHODS
Patients with an HLA 6 antigen serologically
dentical related donor with transfusion-dependent
eta thalassemia major who underwent an allogeneic
CT at our center were included in the analysis.
retransplant Evaluation
All patients were evaluated with a complete blood
ount (CBC), biochemical proﬁle, and serology for
uman immunodeﬁciency virus (HIV), Hepatitus B
irus (HBV), hepatitus C virus (HCV), and cytomega-
ovrius (CMV). A liver biopsy was performed at the
ime of Hickman catheter insertion. Pretransplant pa-
ient and donor DNA were stored for chimerism anal-
sis. All patients were nursed in a positive pressure
EPA ﬁltered transplant unit.
onditioning
Majority (97%) of transplants were conditioned
sing a myeloablative regimen consisting of a combi-
ation of busulphan and cyclophosphamide as previ-
usly reported by us [8]. In 6 cases (all second trans-
lants following early rejection) a reduced-intensity
onditioning (RIC) regimen was used; in the majority
his was Fludarabine based.
one Marrow Harvest
The stem cell source was bone marrow for all
atients. Bone marrow was harvested under general
nesthesia from the iliac crest, and the target cell dose
as 3  108 nucleated cells/kg body weight of the
ecipient. The harvest was collected in ACD with
reservative free heparin using 1-liter harvest bags.
or major ABO-mismatched transplants, red cell de- Mletion was achieved with 6% hydroxyethyl starch and
ravity sedimentation. The product was administered
oon after harvest or processing.
raft-versus-Host Disease (GVHD) Prophylaxis
Cyclosporine and short methotrexate was used as
VHD prophylaxis; cyclosporine was administered at
dose of 2.5 mg/kg intravenously over 4 hours twice
aily starting on day 4, and changed to oral admin-
stration at 5 mg/kg twice daily when mucositis had
esolved. Cyclosporine levels were monitored and the
ose adjusted to achieve a target level of 100-300
g/mL. The methotrexate dose was reduced from 15
g/m2 to 10 mg/m2 on day 1 and to 7 mg/m2 from
0 mg/m2 on days 3, 6, and 11 from 1996, because we
ad noticed a higher incidence of gastrointestinal
leeding in patients with thalassaemia major. If mu-
ositis was severe (Grade IV) or bilirubin 20 mg/L,
he day 6 and day 11 doses were omitted. Acute graft-
ersus-host disease (aGVHD) was treated with dexa-
ethasone or methyl prednisone. Steroid refractory
VHD was treated as per the discretion of the treat-
ng physician.
upportive Care
All patients were nursed in a positive-pressure
EPA ﬁltered transplant unit. None of the patients
eceived prophylactic antibiotics or underwent gut
econtamination. Prophylactic acyclovir was adminis-
ered for the ﬁrst 100 days; it was continued beyond
ay 100 if the patient had GVHD and required addi-
ional immunosuppression. Trimethoprim-sulphame-
hoxazole and oral penicillin prophylaxis was initiated
fter stable engraftment and continued for a year. At
he end of 1 year all patients who did not have evi-
ence of GVHD and were off all immunosuppressive
rugs were vaccinated against polio, diphtheria, teta-
us, hemophilus inﬂuenza, and pneumococcus.
efinitions and Definition of Outcomes
Incidence and severity of GVHD was deﬁned as
er established criteria [9]. Hepatic venocclusive dis-
ase (VOD) was diagnosed according to Baltimore
riteria [10]. Event free survival (EFS) was deﬁned
rom the time of transplant to an event; an event was
rimary graft rejection, death, or recurrence of trans-
usion dependence. Stable mixed chimerism with
ransfusion independence was not considered an event
or this analysis. Overall survival (OS) was deﬁned as
ime from transplant to death because of any cause.
tatistical Analysis
The Mann-Whitney U-test was used to compare
etween the 2 groups. Probabilities of EFS and OS
ollowing transplant were estimated by the Kaplan-
eier method and the signiﬁcance assessed by log-
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A New Stratification Strategy 891ank test. Univariate Cox regression was used to ana-
yze the impact of covariables on EFS. Signiﬁcant
actors were included in a multivariate analysis using a
orward stepwise Cox proportional hazards regression
ethod. Signiﬁcance levels were set at 0.05. Statistical
nalysis was done using SPSS version 11.0.
ESULTS
emographic and Clinical Characteristics
A total of 190 patients with transfusion dependent
thalassemia major underwent 197 transplants be-
ween January 1991 and December 2005 at our center.
he median age of this cohort was 7  4.1 years, and
here were 129 males (68%). There were 11 (5.6%),
1 (41.1%), and 105 (53.3%) transplants in Lucarelli
lass I, II, and III, respectively. The baseline charac-
eristics of patients and their impact on EFS are sum-
arized in Table 1.
isk Factors and Risk Stratification
f Class III Patients
Patient age and liver size as continuous variables
ere signiﬁcantly associated with an adverse outcome.
sing a receiver operating characteristic (ROC) curve
lot analysis, cutoff values of 7 years and 5 cm, respec-
ively, for age and liver size gave the highest likelihood
atios for an adverse effect on EFS (1.8 and 3.5, re-
pectively). These cutoff values signiﬁcantly discrimi-
ated patients’ EFS on a univariate analysis (Table 1).
ther important factors often reported in these pa-
ients and those with a trend to signiﬁcance on EFS in
his analysis are illustrated in Table 1. On a forward
tepwise multivariate analysis only age 7 years and
iver size 5 cm retained their signiﬁcance (relative
isk 2.2 and 2.7, P values .014 and .000, respectively).
sing these 2 variables patients were categorized as
igh risk if they were 7 years and had a liver size 5
able 1. Unadjusted Adverse Effect of Pretransplant Variables on
vent-Free Survival (EFS)
Pretransplant
Variable
Median (range)/
n (%)
RR
(95% CI)
P
Value
ge (>7 years) 104 (52.8) 2.9 (1.6-5.2) .000
ex (F) 63 (32) 1.6 (0.9-2.7) .082
ody mass index 14.8 (9.9-23.8) 0.9 (0.8-1.1) .648
>M 81 (41.1) 0.9 (0.5-1.5) .715
iver size (>5 cm) 52 (26.4) 3.5 (2.1-5.9) .000
helation
(inadequate) 179 (90.9) 2.9 (0.7-12.2) .130
plenectomy (Yes) 30 (15.2) 3.4 (1.9-5.9) .000
iver fibrosis (Yes) 143 (72.6) 1.7 (0.8-3.3) .106
GPT (IU/L) 64 (7-440) 1.0 (1-1.006) .080
erritin (ng/mL) 2916 (925-9052) 1 (1.0-1.0) .020
BsAg positive 5 (2.5%) 1.1 (0.2-8.0) .915
CV positive 28 (14.2%) 1.8 (0.99-3.4) .053tR indicates relative risk.m. There were 41 cases in this subgroup (all were
lass III, Class III high risk group); the remaining
atients in Class III (n  64) were considered as a
ow-risk subset within this group (Class III low risk).
mpact of Pretransplant Splenectomy
Splenectomy was associated with a signiﬁcant ad-
erse impact on clinical outcome in Class III patients.
he baseline characteristics of Class III patients who
ad a pretransplant splenectomy is compared with
hose that did not in Table 2. The splenectomized
atients were signiﬁcantly older and had signiﬁcantly
reater liver size than those that were not (Table 2).
here were also signiﬁcantly more patients who were
lass III high risk in the group of patients who were
plenectomized. Of the 29 patients in Class III who
ad a pretransplant splenectomy, 20 (69%) belonged
o the high-risk group. The Kaplan-Meier 5-year
FS 1 SE for Class III patients who had a pretrans-
lant splenectomy versus those that did not was
1.0%  8.6% and 60.8%  5.98% (P  .003),
espectively (Figure 1). However, when the high-risk
tatus was put into the multivariate analysis, splenec-
omy did not retain a statistically signiﬁcant adverse
mpact, whereas the high-risk stratiﬁcation did.
urvival
At a median follow-up of 48 months (range: 3.2-
54) the Kaplan-Meier 5 year EFS 1 SE (event
eﬁned as primary rejection, recurrence of transfusion
ependence, or death) for Class II and III patients was
8.53%  4.53% and 51.97%  5.14%, respectively.
he 5-year EFS and OS in the Class III high risk
roup (n  41) was 23.93  6.88 and 39.01  7.96,
hereas in the remaining Class III patients (n  64) the
-year EFS and OS was 70.3  6.06 and 78.3  5.5
Figure 2). Statistical analysis of these survival curves
y a log rank test revealed that they were both statis-
able 2. Comparison of Baseline Characteristics of Class III Patients
ho Had a Pretransplant Splenectomy and Those That Did Not
Splenectomy
Variables
Yes (29)
Mean  SD/
n (%)
No (76)
Mean  SD/
n (%)
P
Value
ge (years) 11.7  5.0 8.5  3.5 .003
ex (F) 8 (27.6) 22 (28.9) 1.000
>M 13 (44.8) 28 (36.8) .506
iver size (cm) 5.7  1.8 4.4  1.6 .000
erritin (ng/mL) 4183.0  2222.1 4183.1  1764 .879
GPT (IU/L) 131.7  88.8 113.1  72.3 .324
GOT (IU/L) 94.6  44.8 72.4  37.9 .012
ajor ABO
mismatch 8 (27.6) 20 (26.3) .50
lass III high risk 20 (69) 21 (21.6) .000ically signiﬁcant (P  .000 for both EFS and OS).
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V. Mathews et al.892here was no statistically signiﬁcant difference in EFS
nd OS between Class II and Class III low-risk pa-
ients.
ause of Events
The cause of events among Class III patients in
he high-risk and low-risk group is summarized in
able 3. There were proportionately more cases of
eaths related to veno-occlusive disease, infections,
nd acute GVHD among patients in the high-risk
roup, although none of them attained a statistically
igniﬁcant difference. There was also no signiﬁcant
ifference in the number of rejections between these 2
roups. There were 3 late deaths in the high-risk
Figure 1. Comparison of 5-year EFS of Class III transplants who haFigure 2. Comparison of 5-year EFS of Class III transplants in the highroup on days 421, 645, and 721, respectively; 2 of
hese were because of pneumococcal septicemia and 1
ecause of meningococcemia.
ISCUSSION
In the initial report of risk stratiﬁcation of patients
ith  thalassemia major undergoing an allogeneic
CT using a myeloablative conditioning regimen,
epatomegaly 2 cm, poor quality chelation and por-
al ﬁbrosis were reported to be associated with an
dverse impact on EFS on a univariate analysis. Only
epatomegaly 2 cm retained its adverse impact on a
ultivariate analysis [3]. Based on their observations
transplant splenectomy (n  29) versus those who did not (n  76).-risk group (n  41) and rest of transplants in Class III (n  64).
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A New Stratification Strategy 893he authors had initially classiﬁed patients based on
he presence or absence of hepatomegaly 2 cm and
ortal ﬁbrosis into Class III if both these adverse
actors were present, Class II if only 1 of these factors
ere present, and as Class I if neither were present.
he authors further demonstrated the ability of this
lassiﬁcation to discriminate the EFS and OS between
hese groups. Importantly, in that study age up to 15
ears was not found to impact EFS.
In the subsequent reports from the same group
nadequate chelation (adequate chelation was deﬁned
s initiation of chelation by 18 months from date of
rst transfusion and chelation with deferoxamine ad-
inistered subcutaneously over 8-10 hours/day for at
east 5 days a week) was included as an adverse factor.
he risk stratiﬁcation was then redeﬁned such that
lass 1 patients were those who had none of the 3 risk
actors, Class II had 1 or 2 of these risk factors,
hereas Class III had all 3 risk factors [4]. This risk
tratiﬁcation has since been the established standard
or patients with  thalassemia major undergoing an
llogeneic SCT.
This risk stratiﬁcation has not been validated in
ifferent populations, especially in a group of patients
ith inadequate medical care prior to an allogeneic
CT. As illustrated in this analysis, there is a skewing
f the distribution of patients in such a population,
ith the majority belonging to Class III and a small
roportion of patients in Class I. Further, as substan-
iated by the analysis in this study, there is a wide
eterogeneity in the clinical outcomes of patients in
lass III. Using age 7 years and liver size 5 cm we
ere able to identify a signiﬁcant subset of patients in
lass III (39%) who have a poor clinical outcome
able 3. Cause of Events among Class III Patients in the High- and
ow-Risk Group
Event
High Risk
(n  41)
n (%)
Low Risk
(n  64)
n (%) P Value
ejection
Primary graft failure 2 (4.9) 3 (4.7) 1.000
Early rejection 1 (2.4) 3 (4.7) 1.000
Late rejection 4 (9.8) 3 (4.7) .428
arly death (<100 days)
VOD 6 (14.6) 5 (7.8) .333
Infections 6 (14.6) 5 (7.8) .333
IC bleed 2 (4.9) 1 (1.6) .559
DAH 2 (4.9) 0 (0) .150
Cardiac 1 (2.4) 1 (1.6) 1.000
Hemmorrhagic cystitis 0 (0) 0 (0) —
GVHD 2 (4.9) 0 (0) .150
ate death (>100 days)
Infection 3 (7.3) 0 (0) .057
GVHD 0 (0) 1 (1.6) 1.000
OD indicates venocclusive disease; IC, intracranial; DAH, diffuse
alveolar hemorrhage; GVHD, graft-versus-host disease.ollowing an allogeneic SCT. This subset of Class IIIatients, the Class III high-risk group, as illustrated in
his study has a dismal outcome following an alloge-
eic SCT using the conventional conditioning regi-
ens.
Splenectomy prior to SCT in thalassemia major is
potential surrogate marker for high-risk disease. In
his study it was signiﬁcantly associated with an ad-
erse impact on EFS on a univariate analysis but failed
o retain its signiﬁcance on a multivariate analysis. To
tudy if it signiﬁcantly contributed to the poor clinical
utcome among the Class III high-risk group cases we
ompared the clinical outcomes between those in the
igh risk group who had a splenectomy (n  20)
ersus those who did not (n  21). There was no
igniﬁcant difference in the EFS and OS between
hese 2 groups (data not shown), suggesting that sple-
ectomy did not independently contribute to the ad-
erse outcome in this high-risk group. The limitation
f the small numbers and retrospective nature of this
tudy makes it difﬁcult to conclude that splenectomy
as not an independent adverse factor. A larger pro-
pective trial or a retrospective analysis of a large
ooperative database would be required to clarify this
urther.
This high-risk group could potentially beneﬁt
rom novel conditioning and GVHD prophylaxis reg-
mens. It also identiﬁes a high-risk subset of patients
ho could potentially be candidates for emerging
ovel therapeutic options such as gene therapy, in
iew of their dismal outlook following an allogeneic
CT. Another option in this high-risk subset would be
o consider delaying SCT for a year or 2, and in the
ntervening period subject the patient to an aggressive
ransfusion and chelation regimen; whether such an
pproach will improve the outcome in this group
emains to be proved.
This study also illustrates that the outcome of the
lass III low-risk group was not signiﬁcantly different
rom those in the conventional Class II risk group,
uggesting that they should be managed as would
atients in Class II and alternative approaches should
e restricted to the Class III high-risk subset.
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